Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
Congratulations to Eric Fischer, PhD, our new Chemical Biology Program Director Based in the Department of Cancer Biology, the Chemical Biology Program is a world leader in providing technologies essential to the translation of discoveries in cancer biology to therapeutic applications. With capabilities in Medicinal Chemistry, Structural Biology, Nuclear Magnetic Resonance, Analytical Chemistry, and Computational Chemistry, this program enables strategic collaborations across Dana-Farber to study novel and neglected targets in diverse cancers. Congratulations to Eric, and many thanks to the program's previous leaders, Nathanael Gray, PhD, and Michael Eck, MD, PhD, for their years of dedicated stewardship.
Based in the Department of Cancer Biology, the Chemical Biology Program is a world leader in providing technologies essential to the translation of discoveries in cancer biology to therapeutic applications. With capabilities in Medicinal Chemistry, Structural Biology, Nuclear Magnetic Resonance, Analytical Chemistry, and Computational Chemistry, this program enables strategic collaborations across Dana-Farber to study novel and neglected targets in diverse cancers. Congratulations to Eric, and many thanks to the program's previous leaders, Nathanael Gray, PhD, and Michael Eck, MD, PhD, for their years of dedicated stewardship.
The Department of Cancer Biology performs lab-based research investigating the molecular pathways driving cancer. We use discoveries about the basic functioning of these pathways to develop novel cancer diagnostics and precision treatments.
A major challenge for cancer therapy is the generation of medicines that kill cancer cells while leaving normal cells unharmed. The promise of precision medicine lies in the ability to target the molecular pathways specific to individual cancer types.
Under the leadership of Department Chair Bradley Bernstein, MD, PhD, our 25 independent faculty and more than 300 laboratory personnel combine structural, chemical, genetic, computational, and biochemical approaches to identify molecular vulnerabilities unique to cancer cells, and to generate novel compounds with therapeutic potential.
Our team has contributed directly and indirectly to a new generation of smart drugs such as imatinib (Gleevec) and gefitinib (Iressa) — bringing the promise of precision medicine closer to reality.
To learn more about the many ways you can support Dana-Farber's research initiatives with a philanthropic gift, please contact Rebecca Shortle at 617-632-4215 or rebecca_shortle@dfci.harvard.edu.
View publications by members of the Department of Cancer Biology.
